Arcturus fails to nominate FY17 statement auditor

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said its shareholders did not ratify the appointment of Ernst

Read the full 141 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE